Reproductive Health and HIV Research Unit, Department of Obstetrics and Gynaecology, University of the Witwatersrand, Mayville 4091, South Africa.
Contraception. 2010 Jan;81(1):30-4. doi: 10.1016/j.contraception.2009.07.007.
Weight gain is commonly reported as a side effect of hormonal contraception and can lead to method discontinuation or reluctance to initiate the method. The purpose of this study was to investigate weight change in adolescent (aged 15-19 years) users of depot-medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN), combined oral contraceptives (COCs) and discontinuers of these methods as compared to nonusers of hormonal contraception.
This longitudinal study recruited initiators of DMPA (n=115), NET-EN (n=115), COCs (n=116) and nonusers of contraception (n=144). Participants were followed up for 4-5 years, and details of current contraceptive method, including switching, discontinuing and/or starting hormonal methods were documented at each 6-monthly visit. Women were classified according to their contraceptive histories on completion of the study, and injectable users were combined into one group for analysis. Height, weight and self-reported dieting were recorded at each visit.
There was no difference in mean age or weight between the groups at baseline. Women using DMPA or NET-EN throughout, or switching between the two, had gained an average of 6.2 kg compared to average increases of 2.3 kg in the COC group, 2.8 kg in nonusers and 2.8 kg among discontinued users of any method (p=.02). There was no evidence of a difference in weight gain between women classified as nonobese or classified as overweight/obese in any of the four study groups at baseline.
There is fairly strong evidence that adolescent contraceptive hormonal injectable users appear to gain more weight than COC users, discontinuers and nonusers of contraception.
体重增加是激素避孕的常见副作用,可导致方法停止使用或不愿开始使用该方法。本研究的目的是调查接受 depot-medroxyprogesterone acetate (DMPA)、norethisterone enanthate (NET-EN)、复方口服避孕药 (COC) 的青少年(15-19 岁)使用者以及这些方法的停药者与未使用激素避孕者之间的体重变化。
这项纵向研究招募了 DMPA(n=115)、NET-EN(n=115)、COC(n=116)和未使用者(n=144)的使用者。参与者随访 4-5 年,在每 6 个月的随访中记录当前避孕方法的详细信息,包括切换、停止使用和/或开始激素方法。在研究结束时,根据她们的避孕史对女性进行分类,并将注射使用者组合到一个组进行分析。在每次就诊时记录身高、体重和自我报告的节食情况。
基线时,各组的平均年龄或体重无差异。持续使用 DMPA 或 NET-EN 或在两者之间切换的女性平均体重增加了 6.2 公斤,而 COC 组的平均体重增加了 2.3 公斤,未使用者增加了 2.8 公斤,任何方法的停药者增加了 2.8 公斤(p=.02)。在任何一组中,基线时未被归类为非肥胖或超重/肥胖的女性,在体重增加方面没有差异。
有相当确凿的证据表明,青春期避孕激素注射使用者似乎比 COC 用户、停药者和未使用者增重更多。